With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in important areas within the pharma industry. Investors could see the two ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

EIFO, the export and investment fund of Denmark, and the Novo Nordisk Foundation, an independent Danish enterprise foundation ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE: NVO ).

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a ...

Among them, WW International (WW), formerly known as WeightWatchers, hit a rough patch earlier this year, resulting in WW ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.